1. Dipòsit Digital de la Universitat de Barcelona
  2. Recerca
  3. Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)
  4. Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183106
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCalvet, Xavier-
dc.contributor.authorCarpio, Daniel-
dc.contributor.authorRodriguez Lago, Iago-
dc.contributor.authorGarcia Vicuña, Rosario-
dc.contributor.authorBarreiro de Acosta, Manuel-
dc.contributor.authorJuanola, Xavier-
dc.contributor.authorAguas, Mariam-
dc.contributor.authorCastillo, Concepción-
dc.contributor.authorGratacós, Jordi-
dc.date.accessioned2022-02-11T16:44:29Z-
dc.date.available2022-02-11T16:44:29Z-
dc.date.issued2021-
dc.identifier.citationCalvet, X., Carpio, D., Rodríguez-Lago, I., García-Vicuña, R., Barreiro-de-Acosta, M., Juanola, X., ... & Gratacós, J. (2021). Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterología y Hepatología (English Edition), 44(8), 587-598.ca
dc.identifier.issn2444-3824-
dc.identifier.urihttp://hdl.handle.net/2445/183106-
dc.description.abstractPatients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures. (C) 2021 The Author(s). Published by Elsevier Espana, S.L.U.ca
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengca
dc.publisherElsevierca
dc.relation.isformatofReproducció del document publicat a: https;//doi.org/10.1016/j.gastre.2021.01.003-
dc.relation.ispartofGastroenterología y Hepatología (English Edition), 2021, vol 44, num 8, p. 587-598.-
dc.relation.urihttps;//doi.org/10.1016/j.gastre.2021.01.003-
dc.rightscc by (c) Calvet, Xavier et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationArtritis reumatoide-
dc.subject.classificationMalalties inflamatòries intestinals-
dc.subject.classificationImmunosupressió-
dc.subject.otherRheumatoid arthritis-
dc.subject.otherInflammatory bowel diseases-
dc.subject.otherImmunosuppression-
dc.titleRisk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategiesca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.identifier.pmid33640469-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S021057052100056X-main.pdf476.78 kBAdobe PDFView/Open
Show simple item record


This item is licensed under a Creative Commons License Creative Commons